Did you know?
You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)
If a big pharma does buy out RVX, Hepalink will still have the licence to sell Apabetalone in China and related territory. The BP would collect sales royalties as per the license agreement that RVX and Hepalink currently have in place. Hepalink’s equity in RVX and their China license to sell Apabetalone are two separate things and if a purchasing BP wanted to sell Apabetalone directly in China they would first have to deal directly with Hepalink regarding that license.
